NCT05520151 Influence of Preoperative Immunomodulation by Oral Impact on Postoperative Complications Following Cystectomies & Nephrectomies
| NCT ID | NCT05520151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Intercommunal Robert Ballanger |
| Condition | Urological Manifestations |
| Study Type | INTERVENTIONAL |
| Enrollment | 214 participants |
| Start Date | 2022-11-30 |
| Primary Completion | 2025-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 214 participants in total. It began in 2022-11-30 with a primary completion date of 2025-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.
Eligibility Criteria
Inclusion Criteria: * 18 years of age and older * Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies. * Having expressed their free and informed consent. * Affiliated to a social security scheme Exclusion Criteria: * Immune deficiency. * HIV infection. * Curative surgery for chronic urinary tract infection. * Urgent surgery. * Inability to take oral impact 7 days before surgery. * Unstable psychiatric state. * Infection with COVID 19 during postoperative stay.
Contact & Investigator
Serge NDOKO, MD
PRINCIPAL INVESTIGATOR
Robert ballanger
Frequently Asked Questions
Who can join the NCT05520151 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urological Manifestations. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05520151 currently recruiting?
Yes, NCT05520151 is actively recruiting participants. Contact the research team at serge.ndoko@ght-gpne.fr for enrollment information.
Where is the NCT05520151 trial being conducted?
This trial is being conducted at Aulnay-sous-Bois, France, Montreuil, France.
Who is sponsoring the NCT05520151 clinical trial?
NCT05520151 is sponsored by Centre Hospitalier Intercommunal Robert Ballanger. The principal investigator is Serge NDOKO, MD at Robert ballanger. The trial plans to enroll 214 participants.